Press Releases

Panbela Announces Poster Presentation at American Association for Cancer Research

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models

Panbela Announces Transfer to OTCQB Market

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer

Exceeding Anticipated Timelines with Accelerated Momentum

• Interim Data Analysis Anticipated in Mid-2024
• Expects Full Enrollment by Q1 2025

Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial

Panbela Announces Publication of Clinical Data Titled:

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

• A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.